Lessons Learned From Five Years of Newborn Screening for Severe Combined Immunodeficiency in Israel.
J Allergy Clin Immunol Pract
; 10(10): 2722-2731.e9, 2022 10.
Article
em En
| MEDLINE
| ID: mdl-35487367
ABSTRACT
BACKGROUND:
Implementation of newborn screening (NBS) programs for severe combined immunodeficiency (SCID) have advanced the diagnosis and management of affected infants and undoubtedly improved their outcomes. Reporting long-term follow-up of such programs is of great importance.OBJECTIVE:
We report a 5-year summary of the NBS program for SCID in Israel.METHODS:
Immunologic and genetic assessments, clinical analyses, and outcome data from all infants who screened positive were evaluated and summarized.RESULTS:
A total of 937,953 Guthrie cards were screened for SCID. A second Guthrie card was requested on 1,169 occasions (0.12%), which resulted in 142 referrals (0.015%) for further validation tests. Flow cytometry immune-phenotyping, T cell receptor excision circle measurement in peripheral blood, and expression of TCRVß repertoire for the validation of positive cases revealed a specificity and sensitivity of 93.7% and 75.9%, respectively, in detecting true cases of SCID. Altogether, 32 SCID and 110 non-SCID newborns were diagnosed, making the incidence of SCID in Israel as high as 129,000 births. The most common genetic defects in this group were associated with mutations in DNA cross-link repair protein 1C and IL-7 receptor α (IL-7Rα) genes. No infant with SCID was missed during the study time. Twenty-two SCID patients underwent hematopoietic stem cell transplantation, which resulted in a 91% survival rate.CONCLUSIONS:
Newborn screening for SCID should ultimately be applied globally, specifically to areas with high rates of consanguineous marriages. Accumulating data from follow-up studies on NBS for SCID will improve diagnosis and treatment and enrich our understanding of immune development in health and disease.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunodeficiência Combinada Severa
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Humans
/
Newborn
País/Região como assunto:
Asia
Idioma:
En
Revista:
J Allergy Clin Immunol Pract
Ano de publicação:
2022
Tipo de documento:
Article